



1632
TFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ryuichi Morishita &
Munehisa Shimamura

Application No. 10/517,154

Filed: July 11, 2005

Confirmation No. 2664

For: AGENTS FOR GENE THERAPY OF
CEREBROVASCULAR DISORDERS

Examiner: Paul Thomas Dowell

Art Unit: 1632

Attorney Reference No. 6235-69895-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)

Date Mailed December 9, 2005

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT PURSUANT TO
37 C.F.R. § 1.97(c)**

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement ("IDS") is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Submitted herewith is a Statement Under 37 C.F.R. § 1.97(e) for filing this IDS in compliance with 1.97(c).


Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of this sheet is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,


KLARQUIST SPARKMAN, LLP

By


Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

cc: Docketing



In re application of: Ryuichi Morishita &
Munehisa Shimamura

Application No. 10/517,154

Filed: July 11, 2005

Confirmation No. 2664

For: AGENTS FOR GENE THERAPY OF
CEREBROVASCULAR DISORDERS

Examiner: Paul Thomas Dowell

Art Unit: 1632

Attorney Reference No. 6235-69895-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)

Date Mailed December 9, 2005

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

STATEMENT UNDER 37 C.F.R. § 1.97(e)

1. I, Sheree Lynn Rybak, Ph.D., am the representative for the assignee (AnGes MG, Inc.) of the referenced application.


2. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than 3 months prior to the filing of this statement.

Name: Sheree Lynn Rybak, Ph.D.

December 9, 2005

Date

INFORMATION DISCLOSURE STATEMENT BY APPLICANT



Attorney Docket Number	6235-69895-01
Application Number	10/517,154
Filing Date	July 11, 2005
First Named Inventor	Morishita
Art Unit	1632
Examiner Name	Paul Thomas Dowell

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,652,225	07/29/1997	Isner

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Morishita, R., "Adventure in Gene Therapy: MedGene as the First Academic Genetic Bioventure," Biojapan Symposium Proceedings, pp. 183-193 (Sept. 27, 2000).
		Shimamura et al., "Novel Therapeutic Strategy to Treat Brain Ischemia: Overexpression of Hepatocyte Growth Factor Gene Reduced Ischemic Injury Without Cerebral Edema in Rat Model," Circulation, Vol. 109, No. 3, pages 424-431 (Jan. 27, 2004).
		Yoshimura et al., "Gene Transfer of Hepatocyte Growth Factor to Subarachnoid Space in Cerebral Hypoperfusion Model," Hypertension, Vol. 39, No. 5, pages 1028-1034 (May 2002).

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.